These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34742834)

  • 1. Prediction of pharmacokinetic parameters of inhaled indacaterol formulation in healthy volunteers using physiologically-based pharmacokinetic (PBPK) model.
    Tang C; Ou-Yang CX; Chen WJ; Zou C; Huang J; Cui C; Yang S; Guo C; Yang XY; Lin Y; Pei Q; Yang GP
    Eur J Pharm Sci; 2022 Jan; 168():106055. PubMed ID: 34742834
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bioequivalence studies of inhaled indacaterol maleate in healthy Chinese volunteers under gastrointestinal non-blocking or blocking with concomitant charcoal administration.
    Zou C; Yang Q; Yang S; Zhang X; Yang X; Huang Z; Pei Q; Huang J; Yang G
    Pulm Pharmacol Ther; 2020 Apr; 61():101902. PubMed ID: 32045673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coupled in silico platform: Computational fluid dynamics (CFD) and physiologically-based pharmacokinetic (PBPK) modelling.
    Vulović A; Šušteršič T; Cvijić S; Ibrić S; Filipović N
    Eur J Pharm Sci; 2018 Feb; 113():171-184. PubMed ID: 29054499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lung function, pharmacokinetics, and tolerability of inhaled indacaterol maleate and acetate in asthma patients.
    Miller D; Vaidya S; Jauernig J; Ethell B; Wagner K; Radhakrishnan R; Tillmann HC
    Respir Res; 2020 Sep; 21(1):248. PubMed ID: 32967685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of the predictive capability of modelling and simulation to determine bioequivalence of inhaled drugs: A systematic review.
    Rebello J; Brashier B; Shukla S
    Daru; 2022 Jun; 30(1):229-243. PubMed ID: 35094370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single- and multiple-dose pharmacokinetics of inhaled indacaterol in healthy Chinese volunteers.
    Jiang J; Li L; Yin H; Woessner R; Emotte C; Li R; Khindri S; Pei H
    Eur J Drug Metab Pharmacokinet; 2015 Jun; 40(2):203-8. PubMed ID: 24705947
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of indacaterol and mometasone furoate delivered alone or in a free or fixed dose combination in healthy subjects.
    Vaidya SS; Khindri S; Calder N; Machineni S; Hara H; Majumdar T; Febbraro S; Fuhr R; Woessner R
    Pulm Pharmacol Ther; 2016 Apr; 37():30-6. PubMed ID: 26845343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling Accurately Predicts the Better Bronchodilatory Effect of Inhaled Versus Oral Salbutamol Dosage Forms.
    Boger E; Fridén M
    J Aerosol Med Pulm Drug Deliv; 2019 Feb; 32(1):1-12. PubMed ID: 29878860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of IND/GLY (indacaterol/glycopyrronium) in COPD patients.
    Demin I; Bartels C; Graham G; Bieth B; Gautier A; Tillmann HC; Sechaud R
    Int J Clin Pharmacol Ther; 2016 Jun; 54(6):405-15. PubMed ID: 27049057
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Indacaterol, a novel inhaled, once-daily, long-acting beta2-agonist for the treatment of obstructive airways diseases.
    Beeh KM; Beier J
    Adv Ther; 2009 Jul; 26(7):691-9. PubMed ID: 19609496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):261-75. PubMed ID: 18336055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical benefit of fixed-dose dual bronchodilation with glycopyrronium and indacaterol once daily in patients with chronic obstructive pulmonary disease: a systematic review.
    Ulrik CS
    Int J Chron Obstruct Pulmon Dis; 2014; 9():331-8. PubMed ID: 24729699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches.
    Renard D; Looby M; Kramer B; Lawrence D; Morris D; Stanski DR
    Respir Res; 2011 Apr; 12(1):54. PubMed ID: 21518459
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetic Analysis of Indacaterol/Glycopyrronium/Mometasone Furoate After Administration of Combination Therapies Using the Breezhaler
    Bartels C; Jain M; Yu J; Tillmann HC; Vaidya S
    Eur J Drug Metab Pharmacokinet; 2021 Jul; 46(4):487-504. PubMed ID: 34024035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indacaterol therapy in moderate-to-severe chronic obstructive pulmonary disease: findings from a single-center primary care cohort.
    Singh MP
    Int J Chron Obstruct Pulmon Dis; 2013; 8():613-9. PubMed ID: 24353411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy of indacaterol in chronic obstructive pulmonary disease.
    Ribeiro M; Chapman KR
    Int J Chron Obstruct Pulmon Dis; 2012; 7():145-52. PubMed ID: 22419862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.
    Peters SA
    Clin Pharmacokinet; 2008; 47(4):245-59. PubMed ID: 18336054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Establishment of a clinically relevant specification for dissolution testing using physiologically based pharmacokinetic (PBPK) modeling approaches.
    Kato T; Nakagawa H; Mikkaichi T; Miyano T; Matsumoto Y; Ando S
    Eur J Pharm Biopharm; 2020 Jun; 151():45-52. PubMed ID: 32298756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computed tomography (CT)-assessed bronchodilation induced by inhaled indacaterol and glycopyrronium/indacaterol in COPD.
    Shimizu K; Seto R; Makita H; Suzuki M; Konno S; Ito YM; Kanda R; Ogawa E; Nakano Y; Nishimura M
    Respir Med; 2016 Oct; 119():70-77. PubMed ID: 27692151
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
    Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
    Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.